Barclays raised the firm’s price target on Omada Health (OMDA) to $24 from $21 and keeps an Overweight rating on the shares. The company reported a solid revenue and EBITDA beat in its first quarter as a public company and set fiscal 2025 numbers higher than Street estimates, the analyst tells investors in a research note. The firm expects Omada’s higher membership growth trends to continue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health, Inc.: Strong Market Position and Growth Potential Justify Buy Rating
- Omada Health Reports Strong Q2 2025 Growth
- Omada Health sees FY25 revenue $235M-$241M, consensus $221.84M
- Omada Health reports Q2 EPS (24c), consensus (13c)
- Omada Health’s Strategic Partnerships and AI Leverage Drive Growth and Profitability Outlook